Yayınlar & Eserler

Yayın Ağı
Makaleler 112
Tümü (112)
SCI-E, SSCI, AHCI (102)
SCI-E, SSCI, AHCI, ESCI (106)
ESCI (4)
Scopus (102)
TRDizin (7)
Diğer İndeksler (3)

1. Real-World Treatment Efficacy of Ribociclib or Palbociclib Plus Fulvestrant in Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Turkish Oncology Group (TOG) Study

Kahraman S., Erul E., Gumusay O., Guven D. C., Aksoy S., Basaran G., et al.
Clinical Breast Cancer , cilt.25, sa.5, 2025 (SCI-Expanded, Scopus) identifier identifier

2. The Clinical Outcomes and Safety of Sacituzumab Govitecan in Heavily Pretreated Metastatic Triple-Negative and HR+/HER2- Breast Cancer: A Multicenter Observational Study from Turkey.

Muğlu H., Helvacı K., Köylü B., Yücel M. H., Celayir Ö. M., Demirci U., et al.
Cancers , cilt.17, sa.9, 2025 (SCI-Expanded, Scopus) identifier

3. ASO Visual Abstract: Breast Cancer Recurrence in Initially Clinically Node-Positive Patients Undergoing Sentinel Lymph Node Biopsy after Neoadjuvant Chemotherapy in the NEOSENTITURK-trials MF18-02/18-03

Cabioglu N., Karanlik H., Igci A., Muslumanoglu M., Gulcelik M. A., Uras C., et al.
Annals of surgical oncology , cilt.32, sa.5, ss.3345-3347, 2025 (SCI-Expanded, Scopus) identifier identifier

4. De-Escalation of Nodal Surgery in Clinically Node-Positive Breast Cancer

Cabioǧlu N., Koçer H. B., Karanlik H., Gülçelik M. A., Iǧci A., Müslümanoǧlu M., et al.
JAMA Surgery , cilt.160, sa.3, ss.257-266, 2025 (SCI-Expanded, Scopus) identifier identifier

5. Breast Cancer Recurrence in Initially Clinically Node-Positive Patients Undergoing Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in the NEOSENTITURK-Trials MF18-02/18-03

Cabioglu N., Karanlik H., Igci A., Muslumanoglu M., Gulcelik M. A., Uras C., et al.
Annals of Surgical Oncology , cilt.32, sa.2, ss.952-966, 2025 (SCI-Expanded, Scopus) identifier identifier

6. Real-world data on the efficacy and safety of trastuzumab emtansine in patients with metastatic breast cancer previously treated with pertuzumab: Turkish oncology group multicenter study

Dülgar Ö., Türker S., BAŞARAN G., Araz M., Sümbül A. T., Çağlayan D., et al.
Journal of Chemotherapy , cilt.37, sa.4, ss.334-340, 2025 (SCI-Expanded, Scopus) identifier identifier identifier

7. Combined analysis of the MF18-02/MF18-03 NEOSENTITURK studies: ypN-positive disease does not necessitate axillary lymph node dissection in patients with breast cancer with a good response to neoadjuvant chemotherapy as long as radiotherapy is provided

Muslumanoglu M., Cabioglu N., Igci A., Karanlık H., Kocer H. B., Senol K., et al.
Cancer , cilt.131, sa.1, 2025 (SCI-Expanded, Scopus) identifier identifier

8. Neoadjuvant Pembrolizumab Plus Chemotherapy in Early-Stage Triple-Negative Breast Cancer: A Nationwide Retrospective Turkish Oncology Group Study

KARCI E., BİLİCİ A., Bayram B., Celayir M., Ozyurt N., OYAN ULUÇ B., et al.
CANCERS , sa.19, 2024 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier identifier

9. Final Results of RIGHT Choice: Ribociclib Plus Endocrine Therapy Versus Combination Chemotherapy in Premenopausal Women with Clinically Aggressive Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer

Mahidin E. I. B. M., Im S., Rihani J., Chung W., Babu K. G., Bowles J., et al.
Journal of Clinical Oncology , cilt.42, sa.23, ss.2812-2821, 2024 (SCI-Expanded, Scopus) identifier identifier

10. Beyond traditional therapies: clinical significance of complex molecular profiling in patients with advanced solid tumours-results from a Turkish multi-centre study

ÖLMEZ Ö. F., BİLİCİ A., ER Ö., BİŞGİN A., Sevinc A., Akman T., et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY , sa.5, ss.562-568, 2024 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier identifier

11. Abstract PS01-01: Feasibility and oncological safety of targeted axillary dissection or sentinel lymph node biopsy in patients with clinically node-positive disease after neoadjuvant chemotherapy in the prospective MF-1803 NEOSENTITURK-study

Cabıoğlu N., Karanlik H., Gulcelik M. A., Kocer H. B., Muslumanoglu M., İgci A., et al.
CANCER RESEARCH , cilt.84, sa.9_Supplement, ss.1, 2024 (SCI-Expanded, Scopus)

12. Recommendations for cyclin-dependent kinase 4/6 inhibitor treatments in the context of co-morbidity and drug interactions (Review)

Teomete M., ÇABUK D., Korkmaz T., Seber S., Ozturk O. F., Aver B., et al.
ONCOLOGY LETTERS , cilt.27, sa.4, 2024 (SCI-Expanded, Scopus) Creative Commons License Sürdürülebilir Kalkınma identifier identifier identifier

13. Frequency of germline pathogenic variants in breast cancer predisposition genes among young Turkish breast cancer patients

Isiklar A. D., Aliyeva L., Yesilyurt A., Soyder A., Başaran G.
Breast Cancer Research and Treatment , cilt.202, sa.2, ss.297-304, 2023 (SCI-Expanded, Scopus) identifier identifier

14. Evaluation of bone health in breast cancer patients with germline pathogenic variants

Isiklar A., BAŞARAN G.
EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY , sa.5, ss.148-152, 2023 (SCI-Expanded) Creative Commons License Sürdürülebilir Kalkınma identifier

15. Serologic Response to SARS-CoV-2 Vaccine in Patients with Breast Cancer

Işıklar A., Başaran G., Celayir O. M., Kahraman G., Somanje J., Çolak S. Ö., et al.
Acıbadem Üniversitesi Sağlık Bilimleri Dergisi , cilt.14, sa.3, ss.1-7, 2023 (TRDizin)

16. Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer.

Kahraman S., Erul E., Seyyar M., Gumusay Ö., Bayram E., Demirel B. C., et al.
Future oncology (London, England) , 2023 (SCI-Expanded, Scopus) identifier

17. Impact of adding pertuzumab to trastuzumab plus chemotherapy in neoadjuvant treatment of HER2 positive breast cancer patients: a multicenter real-life HER2PATH study.

Bilici A., Olmez O. F., Kaplan M. A., Oksuzoglu B., Sezer A., Karadurmus N., et al.
Acta oncologica (Stockholm, Sweden) , ss.1-10, 2023 (SCI-Expanded, Scopus) identifier

18. Alpelisib induced interstitial lung disease in a patient with advanced breast cancer

Isiklar A., Basaran G., Sepin B., Gumusay Ö., Kocagoz A. S., Cuhadaroglu Ç.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE , cilt.29, sa.2, ss.484-488, 2023 (SCI-Expanded, Scopus) identifier identifier identifier

19. Demographic and Clinical Features of Patients with Metastatic Breast Cancer: A Retrospective Multicenter Registry Study of the Turkish Oncology Group

DOĞAN İ., AKSOY S., ÇAKAR B., BAŞARAN G., Ercelep O., Mandel N. M., et al.
CANCERS , sa.6, 2023 (SCI-Expanded, Scopus) Creative Commons License identifier

20. What Has Changed in Patients Aged 65 and over Diagnosed with Breast Cancer during the COVID-19 Pandemic: A Single-Center Experience

Soyder A., Güldoğan N., Isıklar A., Arıbal E., Başaran G.
BREAST CARE , cilt.17, sa.4, ss.385-390, 2022 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier identifier identifier

21. Clinical outcome and characteristics of Turkish breast cancer patients during SARS-Cov-2 pandemic: Single center experience.

Isıklar A., Soyder A., Gümüşay Ö., Basaran G.
JOURNAL OF CLINICAL ONCOLOGY , cilt.40, sa.16_suppl, ss.1-5, 2022 (SCI-Expanded, Scopus)

22. Sentinel lymph node biopsy with/without axillary dissection in clinically node-positive breast cancer after neoadjuvant chemotherapy

CABIOĞLU N., KARANLIK H., Gulcelik M. A., Ilgun S., Igci A., URAS C., et al.
ANNALS OF SURGICAL ONCOLOGY , cilt.29, sa.SUPPL 1, ss.69-70, 2022 (SCI-Expanded, Scopus) identifier

23. Real-Life Analysis of Efficacy and Safety of Everolimus Plus Exemestane in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2-Negative Metastatic Breast Cancer Patients: A Turkish Oncology Group (TOG) Study

Bilici A., Uysal M., Menekse S., Akin S., Yildiz F., Turan M., et al.
CANCER INVESTIGATION , cilt.40, sa.2, ss.199-209, 2022 (SCI-Expanded, Scopus) identifier identifier identifier identifier

24. Clinical Outcome and Characteristics of Turkish Breast Cancer Patients who had SARS-Cov-2 Infection

Işiklar A., Zengin R., Balci V., Sesin Kocagöz A. S., BAŞARAN G.
Turk Onkoloji Dergisi , cilt.37, sa.4, ss.419-425, 2022 (ESCI, Scopus) identifier

25. How Do Breast Cancer Patients Present Following COVID-19 Early Peak in a Breast Cancer Center in Turkey?

Isiklar A. D., Deniz C., Soyder A., Guldogan N., Yilmaz E., Basaran G.
EUROPEAN JOURNAL OF BREAST HEALTH , cilt.17, sa.3, ss.253-257, 2021 (ESCI, Scopus, TRDizin) Sürdürülebilir Kalkınma identifier identifier identifier

26. Clinical and pathologic characteristics of Turkish breast cancer (BC) patients screened with BRCA1, BRCA2 or 26-gene inherited cancer panel testing: Single institution experience

Isiklar A., Soyder A., YARARBAŞ K., Ekmekci C., Yazici H., BAŞARAN G.
CANCER RESEARCH , cilt.81, sa.4, 2021 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier

27. Turkish national consensus on breast cancer management during temporary state of emergency due to COVID-19 outbreak

Sezer A., ÇİÇİN İ., Cakmak G. K., Gurdal S. O., Basaran G., Oyan B., et al.
TURKISH JOURNAL OF SURGERY , cilt.36, sa.2, ss.147-163, 2020 (ESCI, Scopus, TRDizin) identifier identifier identifier

28. Approach to Breast Cancer Treatment in Elderly Patients

Seber S., ÇABUK D., BAŞARAN G.
TIBBI ONKOLOJI - GERIATRIK ONKOLOJI , cilt.20, ss.77-87, 2020 (SCI-Expanded) Creative Commons License identifier identifier identifier identifier

29. Efficacy of Palbociclib and Endocrine Treatment in Heavily Pretreated Hormone Receptor-positive/HER2-negative Advanced Breast Cancer: Retrospective Multicenter Trial

Demir A., Mandel N. M., PAYDAŞ S., Demir G., ER O., Turhal N. S., et al.
Balkan medical journal , cilt.37, sa.2, ss.104-107, 2020 (SCI-Expanded, Scopus, TRDizin) Sürdürülebilir Kalkınma identifier identifier identifier

30. Efficacy of Palbociclib and Endocrine Treatment in Heavily Pretreated Hormone Receptor-positive/HER2-negative Advanced Breast Cancer: Retrospective Multicenter Trial.

Demir A., Molinas Mandel N., Paydaş S., Demir O. G., Er Ö., Turhal N. S., et al.
Balkan Medical Journal , cilt.37, sa.2, ss.104-107, 2020 (SCI-Expanded, Scopus, TRDizin) Sürdürülebilir Kalkınma

31. Pembrolizumab for Early Triple-Negative Breast Cancer

Schmid P., Cortes J., Pusztai L., McArthur H., Kuemmel S., Bergh J., et al.
NEW ENGLAND JOURNAL OF MEDICINE , cilt.382, sa.9, ss.810-821, 2020 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier identifier identifier

32. Pertuzumab, trastuzumab and taxane-based treatment for visceral organ metastatic, trastuzumab-naive breast cancer: real-life practice outcomes

Esin E., Oksuzoglu B., Bilici A., ÇİÇİN İ., KÖSTEK O., Kaplan M. A., et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY , cilt.83, sa.1, ss.131-143, 2019 (SCI-Expanded, Scopus) identifier identifier identifier

33. value of second look ultrasonography for MRI detected nonmass enhancing lesions

TAŞKIN F., SOYDER A., kuş a., içten g. e., URAS C.
Acıbadem Sağlık Bilimleri , 2018 (Hakemli Dergi)

34. Ongoing unmet needs in treating estrogen receptor-positive/HER2-negative metastatic breast cancer

Basaran G., Twelves C., Dieras V., Cortes J., Awada A.
CANCER TREATMENT REVIEWS , cilt.63, ss.144-155, 2018 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier identifier identifier

35. COST OF TREATMENT OF HR+/HER2-POST MENOPAUSAL ADVANCED/METASTATIC BREAST CANCER PATIENTS IN TURKEY

Altundag K., Basaran G., Oksuzoglu B., Oven B., ÖZGÜROĞLU M., Aydin D., et al.
VALUE IN HEALTH , sa.3, 2016 (SCI-Expanded, SSCI, Scopus) identifier

36. Review of the current role of targeted therapies as maintenance therapies in first and second line treatment of epithelial ovarian cancer; In the light of completed trials

Korkmaz T., Seber S., Basaran G.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY , cilt.98, ss.180-188, 2016 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier identifier identifier

37. A European Organisation for Research and Treatment of Cancer randomized, double-blind, placebo-controlled, multicentre phase II trial of anastrozole in combination with gefitinib or placebo in hormone receptor-positive advanced breast cancer (NCT00066378)

Tryfonidis K., Basaran G., Bogaerts J., Debled M., Dirix L., Thery J., et al.
EUROPEAN JOURNAL OF CANCER , cilt.53, ss.144-154, 2016 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier identifier identifier

38. Nine weeks versus 1 year adjuvant trastuzumab in patients with early breast cancer: an observational study by the Turkish Oncology Group (TOG)

Icli F., Altundag K., AKBULUT H., PAYDAŞ S., BAŞARAN G., SAİP P. M., et al.
BREAST CANCER , cilt.22, sa.5, ss.480-485, 2015 (SCI-Expanded, Scopus) identifier identifier identifier identifier

39. The Outcome of Patients with Triple Negative Breast Cancer: The Turkish Oncology Group Experience

Eralp Y., Kilic L., Alco G., BAŞARAN G., Dogan M., Dincol D., et al.
JOURNAL OF BREAST HEALTH , cilt.10, sa.4, ss.209-215, 2014 (ESCI) Creative Commons License identifier identifier identifier

40. Clinical Outcome of Turkish Metastatic Breast Cancer Patients with Currently Available Treatment Modalities - Single Center Experience

Cabuk D., BAŞARAN G., Teomete M., Dane F., Korkmaz T., Seber S., et al.
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION , cilt.15, sa.1, ss.117-122, 2014 (SCI-Expanded, Scopus) identifier identifier identifier identifier

41. Associations between clinicopathological prognostic factors and pAkt, pMAPK and topoisomerase II expression in breast cancer

Iyikesici M. S., BAŞARAN G., DANE F., Ekenel M., YUMUK P. F., ÇABUK D., et al.
INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE , cilt.7, sa.5, ss.1459-1464, 2014 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier identifier identifier

42. Phase II study of lapatinib in combination with vinorelbine in patients with HER2 positive recurrent or metastatic breast cancer: A multicentric Turkish Oncology Group (TOG) trial

SAİP P. M., Eralp Y., AYDOĞMUŞ ŞEN F., Karaca H., ÖZKAN M., ÇETİN B. E., et al.
BREAST , cilt.22, sa.5, ss.628-633, 2013 (SCI-Expanded, Scopus) identifier identifier identifier identifier

43. Serum thymidine kinase 1 levels correlates with FDG uptake and prognosis in patients with non small cell lung cancer

Korkmaz T., Seber S., Okutur K., BAŞARAN G., Yumuk F., Dane F., et al.
BIOMARKERS , cilt.18, sa.1, ss.88-94, 2013 (SCI-Expanded, Scopus) identifier identifier identifier identifier

44. Hipokalemik paralizi ile klinik belirti veren adrenokortikal karsinom olgusu

Salman S., Meriçliler Y. Ö., Başaran G.
Acıbadem Üniversitesi Sağlık Bilimleri Dergisi , cilt.4, ss.34-36, 2013 (Hakemli Dergi)

45. The correlates of benefit from neoadjuvant chemotherapy before surgery in non-small-cell lung cancer: a metaregression analysis

Bozcuk H., Abali H., Coskun S., Aydiner A., Çinkaya A., Demirkazik A., et al.
World Journal of Surgical Oncology , cilt.10, 2012 (SCI-Expanded, Scopus) Creative Commons License identifier identifier

46. Docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy followed by concurrent chemoradiotherapy with cisplatin in locally advanced stage III and IV nasopharyngeal cancer.

Dane F., Atasoy B. M., Akgun Z., Yumuk F., Cabuk D., Teomete M., et al.
JOURNAL OF CLINICAL ONCOLOGY , cilt.30, sa.15_suppl, ss.16015, 2012 (SCI-Expanded, Scopus)

47. Prognostic role of initial PET CT SUV max value in metastatic gastric adenocarcinoma

KORKMAZ T., ŞEBER E. S., OKUTUR S. K., CANHOROZ M., BİLİCİ A., TOPTAŞ T., et al.
Mediterranean Oncology Journal , cilt.1, sa.2, ss.35-39, 2012 (Hakemli Dergi)

48. 5-Flourouracil-Induced Encephalopathy in Parkinson's Disease

Korkmaz T., Seber S., BAŞARAN G., Yumuk P. F., Dane F., Kocar M., et al.
UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI , cilt.22, sa.1, ss.51-53, 2012 (SCI-Expanded, Scopus, TRDizin) Sürdürülebilir Kalkınma identifier

49. The access rate to diagnosis and treatment modalities in breast cancer patients in Turkey; multicenter observational study.

Saip P., Keskin S., Ozkan M., Kaplan M. A., Aydogan F., Gonullu Demirag G., et al.
Journal of B.U.ON. : official journal of the Balkan Union of Oncology , cilt.16, sa.4, ss.664-71, 2011 (SCI-Expanded, Scopus) identifier identifier

50. Clinical outcome of breast cancer patients with N3a (>= 10 positive lymph nodes) disease: has it changed over years?

BAŞARAN G., Devrim C., Caglar H. B., GÜLLÜOĞLU M. B., KAYA H., Seber S., et al.
MEDICAL ONCOLOGY , cilt.28, sa.3, ss.726-732, 2011 (SCI-Expanded, Scopus) identifier identifier identifier identifier

51. Weight gain after adjuvant chemotherapy in patients with early breast cancer in Istanbul Turkey

BAŞARAN G., Turhal N. S., Cabuk D., Yurt N., Yurtseven G., Gumus M., et al.
MEDICAL ONCOLOGY , cilt.28, sa.2, ss.409-415, 2011 (SCI-Expanded, Scopus) identifier identifier identifier identifier

52. Prognostic significance of serum thymidine kinase activity (TK1) level in patients with metastatic non-small cell lung cancer (NSCLC)

Korkmaz T., Seber S., BAŞARAN G., Yumuk P. F., Dane F., Okutur K., et al.
JOURNAL OF CLINICAL ONCOLOGY , cilt.29, sa.15, 2011 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier

53. Correlation of high FDG uptake in PET/CT with poor prognosis in metastatic gastric adenocarcinoma.

Canhoroz M., Korkmaz T., Seber S., Bilici A., Okutur K., Toptas T., et al.
JOURNAL OF CLINICAL ONCOLOGY , cilt.29, sa.15, 2011 (SCI-Expanded, Scopus) identifier

54. Nine versus 52 weeks of adjuvant trastuzumab in early breast cancer: An observational study of the Turkish Oncology Group.

Icli F., Altundag K., Coskun U., Paydas S., BAŞARAN G., SAİP P. M., et al.
JOURNAL OF CLINICAL ONCOLOGY , cilt.29, sa.15, 2011 (SCI-Expanded, Scopus) identifier

55. Clinical/pathologic characteristics of diabetic patients with early breast cancer (BC) and their survival outcome

Seber S., BAŞARAN G., Korkmaz T., Telli F., Kocar M., Kanitez M., et al.
JOURNAL OF CLINICAL ONCOLOGY , cilt.29, sa.15, 2011 (SCI-Expanded, Scopus) identifier

56. Phase II study of lapatinib in combination with vinorelbine in patients with ErbB2-amplified recurrent or metastatic breast cancer

SAİP P. M., Eralp Y., Ozkan M., Karaca H., Benekli M., Cetin B., et al.
JOURNAL OF CLINICAL ONCOLOGY , cilt.29, sa.15, 2011 (SCI-Expanded, Scopus) identifier

57. The impact of 21-gene recurrence score (RS) scores on treatment decisions: Retrospective evaluation in Turkish early-stage breast cancer (BC) patients

BAŞARAN G., Saglam S., Tansan S., Demirel M., Gokmen E., Aktan S., et al.
JOURNAL OF CLINICAL ONCOLOGY , cilt.29, sa.15, 2011 (SCI-Expanded, Scopus) identifier

58. Prognostic significance of serum thymidine kinase activity (TK1) level in patients with metastatic non-small cell lung cancer (NSCLC)

Korkmaz T., Seber S., BAŞARAN G., Yumuk P. F., Dane F., Okutur K., et al.
JOURNAL OF CLINICAL ONCOLOGY , cilt.29, sa.15, 2011 (SCI-Expanded, Scopus) identifier

59. The changing pattern of risk factors and disease characteristics of breast cancer in Turkey: A cross-sectional study of a Turkish oncology group (BREASTTURK)

AKBULUT H., Altundag M. K., SAİP P. M., Coskun H. S., Camci C., Ozkan M., et al.
JOURNAL OF CLINICAL ONCOLOGY , cilt.29, sa.15, 2011 (SCI-Expanded, Scopus) identifier

60. Efficacy, safety and prognostic features of resected colon carcinoma treated in "real world" practice: a retrospective cohort-study

Dane F., Ozturk M. A., Gumus M., Guven A., ALİUSTAOĞLU M., Cabuk D., et al.
JOURNAL OF BUON , cilt.16, sa.2, ss.257-264, 2011 (SCI-Expanded, Scopus) identifier identifier identifier

61. Primary breast mantle cell lymphoma with atypical relapse patterns.

Dane F., Seker M., Fulden Yumuk P., Gunduz F., Peker O., Basaran G., et al.
Journal of B.U.ON. : official journal of the Balkan Union of Oncology , cilt.16, sa.1, ss.181-2, 2011 (SCI-Expanded, Scopus) identifier identifier

62. Pulmonary toxicity in patients receiving docetaxel chemotherapy

Yumuk P. F., KEFELİ U., CEYHAN B., Dane F., Eroglu B. T., Gumus M., et al.
MEDICAL ONCOLOGY , cilt.27, sa.4, ss.1381-1388, 2010 (SCI-Expanded, Scopus) identifier identifier identifier identifier

63. Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine Alone in Treatment of Favorable, Limited-Stage Hodgkin's Lymphoma: Do We Really Have Robust Data?

BAŞARAN G., Agaoglu F., BAŞARAN M.
JOURNAL OF CLINICAL ONCOLOGY , cilt.28, sa.27, 2010 (SCI-Expanded, Scopus) identifier

64. How much do Turkish women know about breast cancer prevention?

Basaran G., Yilmaz D., Bingol I., Kizlitac U.
JOURNAL OF CLINICAL ONCOLOGY , cilt.28, sa.15, 2010 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier

65. Weight gain after adjuvant chemotherapy in early breast cancer patients in Istanbul.

Turhal N. S., BAŞARAN G., Yurt N., Yurtseven G., Cabuk D., Teomete M., et al.
JOURNAL OF CLINICAL ONCOLOGY , cilt.28, sa.15, 2010 (SCI-Expanded, Scopus) identifier

66. The association between individual attachment patterns, the perceived social support, and the psychological well-being of Turkish informal caregivers

Kuscu M. K., DURAL ŞENOĞUZ U., Oenen P., Yasa Y., Yayla M., Basaran G., et al.
PSYCHO-ONCOLOGY , cilt.18, sa.9, ss.927-935, 2009 (SCI-Expanded, SSCI, Scopus) identifier identifier identifier identifier

67. A case of Kikuchi-Fujimoto disease misdiagnosed as Hodgkin's lymphoma: the importance of second opinion.

Dane F., Ozturk M. A., Tecimer T., Atasoy B. M., Cabuk D., Yumuk P. F., et al.
Journal of B.U.ON. : official journal of the Balkan Union of Oncology , cilt.14, sa.2, ss.309-11, 2009 (SCI-Expanded, Scopus) identifier identifier

68. Prolonged interval in prophylactic heparin flushing for maintenance of subcutaneous implanted port care in patients with cancer

KEFELİ U., Dane F., Yumuk P. F., Karamanoglu A., Iyikesici S., Basaran G., et al.
EUROPEAN JOURNAL OF CANCER CARE , cilt.18, sa.2, ss.191-194, 2009 (SCI-Expanded, Scopus) identifier identifier identifier identifier

69. Benefit from adjuvant anthracyclines according to hormone receptor status

BAŞARAN G., Cabuk D., Teomete M., GÜLLÜOĞLU M. B., KAYA H., Dane F., et al.
JOURNAL OF CLINICAL ONCOLOGY , cilt.26, sa.15, 2008 (SCI-Expanded, Scopus) identifier

70. Clinical features and outcome of adjuvant chemoradiotherapy in Turkish rectal carcinoma patients: Single institution experience

Dane F., Gumus M., Ozturk M. A., Cabuk D., Atasoy M. B., Yumuk P. F., et al.
JOURNAL OF CLINICAL ONCOLOGY , cilt.26, sa.15, 2008 (SCI-Expanded, Scopus) identifier

71. Clinical outcome of triple-negative (TN) breast cancer (BC)

Cabuk D., BAŞARAN G., Kaya H., Gulluoglu B., Teomete M., Dane F., et al.
JOURNAL OF CLINICAL ONCOLOGY , cilt.26, sa.15, 2008 (SCI-Expanded, Scopus) identifier

72. Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer

Piccart-Gebhart M. J., Burzykowski T., Buyse M., Sledge G., Carmichael J., Lueck H., et al.
JOURNAL OF CLINICAL ONCOLOGY , cilt.26, sa.12, ss.1980-1986, 2008 (SCI-Expanded, Scopus) Creative Commons License identifier identifier identifier identifier

73. Anti-tumor activity of capecitabine and vinorelbine in patients with anthracycline- and taxane-pretreated metastatic breast cancer: Findings from the EORTC 10001 randomized phase II trial

Pajk B., Cufer T., Canney P., Ellis P., Cameron D., Blot E., et al.
BREAST , cilt.17, sa.2, ss.180-185, 2008 (SCI-Expanded, Scopus) identifier identifier identifier identifier

74. Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer

Burzykowski T., Buyse M., Piccart-Gebhart M. J., Sledge G., Carmichael J., Lueck H., et al.
JOURNAL OF CLINICAL ONCOLOGY , cilt.26, sa.12, ss.1987-1992, 2008 (SCI-Expanded, Scopus) identifier identifier identifier identifier

75. Impact of body mass index on cancer development

Yumuk P. F., Dane F., Yumuk V. D., Yazici D., Ege B., BEKİROĞLU G. N., et al.
JOURNAL OF BUON , cilt.13, sa.1, ss.55-59, 2008 (SCI-Expanded, Scopus) identifier identifier identifier

76. Clinical outcome of rhabdomyosarcoma in adolescent and adult patients: Single center experience from Turkey

Ustuner Z., BAŞARAN M., Dizdar Y., Agaoglu F., BİLGİÇ M. B., ŞAKAR B., et al.
TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE , cilt.213, sa.3, ss.221-229, 2007 (SCI-Expanded, Scopus) Creative Commons License Sürdürülebilir Kalkınma identifier

77. P2-323: Outcome of patients with stage III and IV non-small cell lung cancer in Marmara University Hospital, Istanbul, Turkey

Yumuk P. F., Teomete M., Dane F., Cabuk D., Caglar H. B., Abacioglu U., et al.
JOURNAL OF THORACIC ONCOLOGY , cilt.2, sa.8, ss.701, 2007 (SCI-Expanded, Scopus)

78. Epithelioid hemangioendothelioma with multiple organ involvement

Celikel C., Yumuk P. F., BAŞARAN G., Yildizeli B., Kodalli N., Ahiskali R.
APMIS , cilt.115, sa.7, ss.881-888, 2007 (SCI-Expanded, Scopus) identifier identifier identifier identifier

79. Outcome of metastatic colorectal cancer patients receiving second line chemotherapy in Marmara University Hospital

Dane F., GÜMÜŞ M., ÖZTÜRK A., Yumuk F., Iyikesici S., BAŞARAN G., et al.
JOURNAL OF CLINICAL ONCOLOGY , cilt.25, sa.18, 2007 (SCI-Expanded, Scopus) identifier

80. The role of adjuvant chemoradiotherapy (CRT) in Turkish patients with gastric carcinoma

Gumus M., Dane F., Kaya S., Ozturk M. A., Yumuk P. F., Atasoy B. M., et al.
JOURNAL OF CLINICAL ONCOLOGY , cilt.25, sa.18, 2007 (SCI-Expanded, Scopus) identifier

81. Clinical outcome of node-negative (NN) breast cancer (BC) patients

BAŞARAN G., Cabuk D., Dane F., Teomete M., Iyikesici S., Meltem E., et al.
JOURNAL OF CLINICAL ONCOLOGY , cilt.25, sa.18, 2007 (SCI-Expanded, Scopus) identifier

82. Concomitant administration of uracil-tegafur and leucovorin during adjuvant radiotherapy for locally advanced rectal cancer

ATASOY B. M., ABACIOGLU M. U., Dane F., Ozgen Z., Yumuk P. F., Ozden S., et al.
JOURNAL OF BUON , cilt.12, sa.2, ss.203-208, 2007 (SCI-Expanded, Scopus) identifier identifier identifier

83. Vascular endothelial growth factor, hypoxia-inducible factor 1 alpha and CD34 expressions in early-stage gastric tumors: Relationship with pathological factors and prognostic impact on survival

Cabuk D., BAŞARAN G., Celikel C., Dane F., Yumuk P. F., Iyikesici M. S., et al.
ONCOLOGY , cilt.72, sa.1-2, ss.111-117, 2007 (SCI-Expanded, Scopus) identifier identifier identifier identifier

84. HPV DNA frequency and subset analysis in human breast cancer patients' normal and tumoral tissue samples

Gumus M., Yumuk P. F., Salepci T., ALİUSTAOĞLU M., Dane F., EKENEL M., et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH , cilt.25, sa.4, ss.515-521, 2006 (SCI-Expanded) identifier identifier identifier

85. Ewing's sarcoma of the rectum: Are four cycles of chemotherapy enough?

ŞAKAR B., BAŞARAN G., BAŞARAN M.
JOURNAL OF CLINICAL ONCOLOGY , cilt.23, sa.24, ss.5849-5850, 2005 (SCI-Expanded, Scopus) identifier identifier identifier identifier

86. Chemoradiotherapy for localized non-Hodgkin's lymphoma: Lessons from old studies

BAŞARAN G., BAŞARAN M., Onat H.
JOURNAL OF CLINICAL ONCOLOGY , cilt.23, sa.13, ss.3161-3162, 2005 (SCI-Expanded, Scopus) identifier identifier identifier identifier

87. What is the optimal number of lymph nodes to be dissected in colorectal cancer surgery?

Gumus M., Yumuk P., Atalay G., ALİUSTAOĞLU M., Macunluoglu B., Dane F., et al.
TUMORI JOURNAL , cilt.91, sa.2, ss.168-172, 2005 (SCI-Expanded, Scopus) identifier identifier identifier

88. Does the incidence of anal canal cancers differ in Moslem societies?

Yumuk P., ABACIOGLU M. U., Demir G., Cabuk D., Dane F., Gumus M., et al.
INTERNATIONAL JOURNAL OF COLORECTAL DISEASE , cilt.20, sa.1, ss.76, 2005 (SCI-Expanded, Scopus) identifier identifier identifier identifier

89. The role of anti-CENP-B and anti-SS-B antibodies in breast cancer

Atalay C., Atalay G., Yilmaz K., Altinok Y.
NEOPLASMA , cilt.52, sa.1, ss.32-35, 2005 (SCI-Expanded, Scopus) identifier identifier identifier

90. D-dimer - Can it be a marker for malignant gastric lesions?

ALİUSTAOĞLU M., Yumuk P., Gumus M., EKENEL M., Bolukbas F., Bolukbas C., et al.
ACTA ONCOLOGICA , cilt.43, sa.8, ss.770-771, 2004 (SCI-Expanded, Scopus) identifier identifier identifier identifier

91. Lokal İleri ve Metastatik Küçük Hücreli Dışı Akciğer Kanseri Hastalarının Değerlendirilmesi Marmara Üniversitesi Deneyimi

Yumuk P. F., Iyikesici M. S., Gümüş M., Aliustaoğlu M., Dane F., Başaran G., et al.
Türk Onkoloji Dergisi , cilt.19, sa.3, ss.106-111, 2004 (TRDizin) Sürdürülebilir Kalkınma

92. Remaining controversies in the upfront management of advanced ovarian cancer.

Mano M., Awada A., Minisini A., Atalay G., Lago L., Cardoso F., et al.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society , cilt.14, ss.707-20, 2004 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier identifier identifier

93. Attitude toward genetic testing for cancer risk in Istanbul

Yumuk P., Gumus M., EKENEL M., BAŞARAN G., ALİUSTAOĞLU M., Topal A., et al.
GENETIC TESTING , cilt.8, sa.2, ss.169-173, 2004 (SCI-Expanded) identifier identifier identifier identifier

94. What is the effect of systemic anticancer treatment on cognitive function?

Minisini A., Atalay G., Bottomley A., Puglisi F., Piccart M., Biganzoli L.
LANCET ONCOLOGY , cilt.5, sa.5, ss.273-282, 2004 (SCI-Expanded, Scopus) identifier identifier identifier

95. The effect of exemestane on serum lipid profile in postmenopausal women with metastatic breast cancer: a companion study to EORTC Trial 10951, 'Randomized phase II study in first line hormonal treatment for metastatic breast cancer with exemestane or tamoxifen in postmenopausal patients'.

Atalay G., Dirix L., Biganzoli L., Beex L., Nooij M., Cameron D., et al.
Annals of oncology : official journal of the European Society for Medical Oncology , cilt.15, ss.211-7, 2004 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier identifier identifier

96. Treatment outcomes in non-small cell lung cancer (NSCLC) patients: Comparison between Marmara University, Istanbul, Turkey and Knoxville, Tennessee

Iyikesici S., Turhal N. S., Yumuk P. F., Dane F., Gumus M., BAŞARAN G., et al.
ANNALS OF ONCOLOGY , cilt.15, ss.195-196, 2004 (SCI-Expanded, Scopus) identifier

97. Clinical outcome of breast cancer (BC) patients (pts) with pT1N0M0 disease

BAŞARAN G., EKENEL M., Demirkalem P., Cakir T., GÜLLÜOĞLU M. B., Gumus M., et al.
ANNALS OF ONCOLOGY , cilt.15, ss.68, 2004 (SCI-Expanded, Scopus) identifier

98. Clinical features and adjuvant treatment outcomes of colon cancer (cc) in two outpatient populations of Knoxville, Tennessee and Istanbul, Turkey

Dane F., Turhal N. S., Lyikesici S., Gumus M., Yumuk P. F., BAŞARAN G., et al.
ANNALS OF ONCOLOGY , cilt.15, ss.95, 2004 (SCI-Expanded, Scopus) identifier

99. Clinical outcome of breast cancer patients with liver metastases alone in the anthracycline-taxane era: a retrospective analysis of two prospective, randomised metastatic breast cancer trials.

Atalay G., Biganzoli L., Renard F., Paridaens R., Cufer T., Coleman R., et al.
European journal of cancer (Oxford, England : 1990) , cilt.39, ss.2439-49, 2003 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier identifier identifier

100. The pipeline of new anticancer agents for breast cancer treatment in 2003.

Awada A., Cardoso F., Atalay G., Giuliani R., Mano M., Piccart M.
Critical reviews in oncology/hematology , cilt.48, ss.45-63, 2003 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier identifier identifier

101. Second-line treatment in advanced colon cancer: are multiple phase II trials informative enough to guide clinical practice?

Atalay G., Cardoso F., Paesmans M., Goldberg R., Bleiberg H.
Anti-cancer drugs , cilt.14, ss.703-13, 2003 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier identifier identifier

102. Novel therapeutic strategies targeting the epidermal growth factor receptor (EGFR) family and its downstream effectors in breast cancer.

Atalay G., Cardoso F., Awada A., Piccart M.
Annals of oncology : official journal of the European Society for Medical Oncology , cilt.14, ss.1346-63, 2003 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier identifier identifier

103. An EORTC phase I study of capecitabine (Xeloda) in combination with fixed doses of cyclophosphamide and epirubicin (cex) as primary treatment for large operable or locally advanced/inflammatory breast cancer.

Bonnefoi H., Biganzoli L., Mauriac L., Cufer T., Schaefer P., Atalay G., et al.
European journal of cancer (Oxford, England : 1990) , cilt.39, ss.1277-83, 2003 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier identifier identifier

104. Neoplastic diseases prevalence in a turkish university hospital.

Turhal N. S., Aliustaoglu M., Gurses I., Gumus M., Atalay G., Karamanoglu A., et al.
Journal of B.U.ON. : official journal of the Balkan Union of Oncology , cilt.8, sa.1, ss.45-8, 2003 (Scopus) identifier identifier

105. Letrozole's superiority over progestins and tamoxifen challenges standards of care in endocrine therapy for metastatic breast cancer.

Piccart M., Cardoso F., Atalay G.
European journal of cancer (Oxford, England : 1990) , 2002 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier identifier identifier

106. Predictive molecular markers in the adjuvant therapy of breast cancer: state of the art in the year 2002.

Di L., Cardoso F., Durbecq V., Giuliani R., Mano M., Atalay G., et al.
International journal of clinical oncology , cilt.7, ss.245-53, 2002 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier identifier

107. The effects of nitric oxide donors and inhibitors on neutrophil functions in Behcet's disease

Atalay G., Eksioglu-Demiralp E., Akoglu T., DİRESKENELİ R. H.
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY , cilt.20, sa.4, 2002 (SCI-Expanded, Scopus) identifier identifier identifier

108. Predictive factors associated with axillary lymph node metastasis(ALNM) in T1, T2 and T3 breast carcinomas

Atalay G., Gumus M., Aliustaoglu M., Turhal N.
EUROPEAN JOURNAL OF CANCER , cilt.38, 2002 (SCI-Expanded, Scopus) identifier

109. Progress in systemic therapy for breast cancer

Piccart M., Cardoso F., Atalay G., Biganzoli L.
EUROPEAN JOURNAL OF CANCER , cilt.38, 2002 (SCI-Expanded, Scopus) identifier

110. Rectodynamic and radiological assessment in modified Mainz pouch II cases

Gumus E., Miroglu C., Saporta L., Basaran G., Horasanli K., Tanriverdi O., et al.
EUROPEAN UROLOGY , cilt.38, sa.3, ss.316-322, 2000 (SCI-Expanded, Scopus) identifier identifier identifier identifier

111. Amantadine monotherapy of chronic hepatitis C patients infected with genotype 1b

Senturk H., Mert A., Akdogan M., TABAK Ö. F., Basaran G., Turkoglu S., et al.
SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES , cilt.32, sa.5, ss.575-576, 2000 (SCI-Expanded, Scopus) identifier identifier identifier identifier

112. Endocarditis prophylaxis for transrectal prostatic biopsy

Basaran G.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION , cilt.280, sa.22, ss.1908, 1998 (SCI-Expanded, Scopus) identifier identifier identifier identifier
Hakemli Bilimsel Toplantılarda Yayımlanmış Bildiriler 52

1. Artificial intelligence algorithms for recurrence risk score prediction in early-stage breast cancer: A multicenter study of 437 cases

Bayram E., Basaran G., Gokmen E., Mandel N. M., Oyan B., Uskent N., et al.
Special Clinical Science Symposia, ELECTR NETWORK, 29 Mayıs 2024, (Özet Bildiri) identifier

2. Combined Analysis of the MF18-02/03 Neosentiturk Studies: Factors Predicting Recurrence in ycN0/ypN-positive Breast Cancer with Sentinel Lymph Node Biopsy - Or Targeted Axillary Dissection - Alone After Neoadjuvant Chemotherapy

CABIOĞLU N., Muslumanoglu M., Igci A., KARANLIK H., TÜKENMEZ M., Gulcelik M. A., et al.
24th Annual Meeting of The American Society of Breast Surgeons (ASBrS), Mississippi, Amerika Birleşik Devletleri, 26 - 30 Nisan 2023, (Özet Bildiri) identifier

3. Demographic and clinical features of patients with metastatic HER2 positive breast cancer: a retrospective multicenter registry study of the Turkish Oncology Group

Eralp Y., Dogan I., AKSOY S., Cakar B., Basaran G., Ercelep O., et al.
San Antonio Breast Cancer Symposium, San-Antonio, Kuzey Mariana Adaları, 6 - 10 Aralık 2022, (Özet Bildiri) identifier

4. AXILLARY NODAL RECURRENCE IS RARE IN PATIENTS WITH NODE-POSITIVE BREAST CANCER UNDERGOING SLNB FOLLOWING NEOADJUVANT CHEMOTHERAPY : EARLY RESULTS OF THE NEOSENTITURK-TRIAL/MF-18-03

Cabioglu N., KARANLIK H., Gulcelik M. A., Igci A., Muslumanoglu M., Kocer H. B., et al.
San Antonio Breast Cancer Symposium, San-Antonio, Kuzey Mariana Adaları, 6 - 10 Aralık 2022, (Özet Bildiri) identifier

5. Clinical outcome and characteristics of Turkish breast cancer patients during SARSCov-2 pandemic: Single center experience.

Isoklar A., Soyder A., Gumusay O., Basaran G.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 3 - 07 Haziran 2022, (Özet Bildiri) identifier

6. Real-life analysis of pathologic complete response with neoadjuvant trastuzumab plus taxane with or without pertuzumab therapy in HER2 positive locally-advanced breast cancer (HER2PATH Study).

Bilici A., Olmez O. F., Sezer A., Oksuzoglu B., Kaplan M. A., Karadurmus N., et al.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 3 - 07 Haziran 2022, (Özet Bildiri) identifier

7. The effect of the use of complex molecular profiling in advanced solid organ tumours on clinical decision: Turkey molecular profiling in advanced cancers trial (TUMPACT)

Olmez O. F., Bilici A., ER O., Sevinc A., Akman T., Uslu R., et al.
ESMO Virtual Congress, ELECTR NETWORK, 19 Eylül - 18 Ekim 2020, cilt.31, (Özet Bildiri) identifier

8. Retrospective analysis of ribociclib and letrozole as first-line therapy in patients with hormone receptor (HR) positive metastatic breast cancer (MBC) within a managed access program (MAP) in Turkey

Başaran G., Demirci U., Yıldız F., Çiçin İ., Aktaş B. Y., Öztürk B., et al.
American Society of Clinical Oncology (ASCO) Annual Meeting, Illinois, Amerika Birleşik Devletleri, 29 - 31 Mayıs 2020, ss.13055, (Özet Bildiri) Sürdürülebilir Kalkınma

9. Retrospective analysis of ribociclib and letrozole as first-line therapy in patients with hormone receptor (HR) positive metastatic breast cancer (MBC) within a managed access program (MAP) in Turkey.

Basaran G., Demirci U., Yildiz F., Cicin I., Aktas B. Y., Ozturk B., et al.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 29 - 31 Mayıs 2020, cilt.38, (Özet Bildiri) identifier

10. Ribociclib for the treatment of hormone receptor-positive refractory advanced breast cancer: Managed access programme in Turkey

Demirci U., GÖKMEN E., Eralp Y., Gunduz S., SEZGİN GÖKSU S., KORKMAZ T., et al.
42nd Annual San Antonio Breast Cancer Symposium, San-Antonio, Kuzey Mariana Adaları, 9 - 14 Aralık 2019, cilt.80, (Özet Bildiri) Sürdürülebilir Kalkınma identifier

11. The importance of primary surgery in patients with de novo stage IV BC surviving at least 5 years: Protocol MF07-01 randomized clinical trial

ÖZMEN V., ÖZBAŞ S., KARANLIK H., MÜSLÜMANOĞLU M. E., İĞCİ A., CANTÜRK N. Z., et al.
44th ESMO congress, BARSELONA, İspanya, 27 Eylül - 01 Ekim 2019, cilt.30, (Özet Bildiri)

12. Clinical, Radiological and Pathological Findings in Breast Cancer Patients Younger than 30

TAŞKIN F., SOYDER A., ERDOĞDU H. İ., YILDIZ I., KARA H., İÇTEN S. G., et al.
Breastanbul 2018 3rd Breast Cancer Conference, İstanbul, Türkiye, 11 - 13 Ekim 2018, (Özet Bildiri) Sürdürülebilir Kalkınma

13. Pertuzumab, trastuzumab and taxane combination for visceral organ metastatic patients: Real life practice results

Esin E., Oksuzoglu O. B. C., Bilici A., ÇİÇİN İ., AKSOY S., Alacacioglu A., et al.
43rd ESMO Congress (ESMO), Munich, Almanya, 19 - 23 Ekim 2018, cilt.29, ss.104-105, (Özet Bildiri) identifier

14. TÜRKIYE’DE METASTATIK MEME KANSERINDE HER2 HEDEFLITEDAVIDE PERTUZUMAB KULLANIMI ERKEN DÖNEM GÜVENLILIKVERILERI

ESİN E., ÇAKMAK ÖKSÜZOĞLU Ö. B., SAKİN A., YILDIRIM N., ÇABUK D., KARAAĞAÇ M., et al.
7. TÜRK TIBBİ ONKOLOJİ KONGRESİ, Türkiye, 21 - 24 Mart 2018, (Özet Bildiri)

15. High Ki67 levels are significantly correlated with 21-gene assay recurrence scores

Uras C., Boler D. E., Kara H., Basaran G., Balci L., Tokat F., et al.
10th European Breast Cancer Conference (EBCC), Amsterdam, Hollanda, 9 - 11 Mart 2016, cilt.57, (Özet Bildiri) identifier

16. Mutation analysis of the BRCA1 and BRCA2 genes in Turkish patients with breast cancer.

Apessos A., Tsoulos N., Papadopoulou E., Metaxa-Mariatou V., Agiannitopoulos K., Tansan S., et al.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, Amerika Birleşik Devletleri, 29 Mayıs - 02 Haziran 2015, cilt.33, (Özet Bildiri) Sürdürülebilir Kalkınma identifier

17. Prognostic role of progesterone receptor (PR) expression by immunohistochemistry (IHC) in relation to Oncotype recurrence scores (RS).

Basaran G., Korkmaz T., Kara H., Boler D., Kapucuoglu N., Uras C., et al.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, Amerika Birleşik Devletleri, 29 Mayıs - 02 Haziran 2015, cilt.33, (Özet Bildiri) identifier

18. Prognostic role of progesterone receptor expression by immunohistochemistry in relation to oncotype recurrence scores

KORKMAZ T., BAŞARAN G., KAPUCUOGLU N., SAĞLICAN Y., BEŞE N., İÇTEN G. E., et al.
ınternational İstanbul Breast Cancer Conference, İstanbul, Türkiye, 30 Eylül - 02 Ekim 2014

19. Systemic ritoximab immunotherapy in the management of primary ocular adoexal lymphoma: Slagle institution experience.

Tuncer S., Basaran M., Tanyildiz B., Buyukbabani N., Basaran G., Dogan O.
50th Annual Meeting of the American-Society-of-Clinical-Oncology, Illinois, Amerika Birleşik Devletleri, 30 Mayıs - 03 Haziran 2014, cilt.32, (Özet Bildiri) identifier

20. Clinical and pathologic characteristics of patients with breast cancer and a second non-breast primary tumor.

Basaran G., Yazar A., Uras C., Tezcanli E. K., Cabuk D., Atalar B., et al.
49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 31 Mayıs - 04 Haziran 2013, cilt.31, (Özet Bildiri) Sürdürülebilir Kalkınma identifier

21. Kişiye özel meme kanseri tedavisinde ki67 oranlarının Oncotype Dx skorlarıyla korelasyonu

URAS C., CABIOĞLU N., TOKAT F., BAŞARAN G., ER YAZAR Ö., BÖLER D., et al.
18. Ulusal Cerrahi kongresi, İzmir, Türkiye, 23 - 27 Mayıs 2012, (Özet Bildiri) Sürdürülebilir Kalkınma

22. Docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy followed by concurrent chemoradiotherapy with cisplatin in locally advanced stage III and IV nasopharyngeal cancer.

Dane F., Atasoy B. M., Akgun Z., Yumuk F., Cabuk D., Teomete M., et al.
48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 1 - 06 Haziran 2012, cilt.30, (Özet Bildiri) identifier

23. High Ki67 Values Are Significantly Correlated with Oncotype DX Scores

URAS C., CABIOĞLU N., Tokat F., BAŞARAN G., Boler D., ATALAR B., et al.
8th European Breast Cancer Conference (EBCC), Vienna, Avusturya, 21 - 24 Mart 2012, cilt.48, (Özet Bildiri) identifier

24. Taxanes as adjuvant therapy for breast cancer

BAŞARAN G.
European Breast Cancer Conference, Barcelona, İspanya, 24 Mart 2010, cilt.8, ss.17, (Özet Bildiri) identifier

25. Clinical outcome of Turkish metastatic breast cancer patients with currently available treatment modalities. Single center experience

Cabuk D., BAŞARAN G., Korkmaz T., Seber S., Dane F., Telli F., et al.
European Breast Cancer Conference, Barcelona, İspanya, 24 Mart 2010, cilt.8, ss.205, (Özet Bildiri) identifier

26. Immunohistochemically Defined T1N0 Breast Cancer Subgroups Have Different Clinical Outcomes. A Retrospective Turkish Oncology Group Study

BAŞARAN G., Okkan S., Caglar H., Benekli M., Gumus M., Haydaroglu A., et al.
32nd Annual San Antonio Breast Cancer Symposium, San-Antonio, Kuzey Mariana Adaları, 9 - 13 Aralık 2009, cilt.69, (Özet Bildiri) Sürdürülebilir Kalkınma identifier

27. Impact of dose reductions of platinum compounds on survival in stage IIIB/IV non-small cell lung cancer (NSCLC)

Yumuk P. F., Teomete M., Dane F., Cabuk D., BAŞARAN G., Turhal N. S.
45th Annual Meeting of the American-Society-of-Clinical-Oncology, Florida, Amerika Birleşik Devletleri, 29 Mayıs - 02 Haziran 2009, cilt.27, (Özet Bildiri) identifier

28. Pulmonary toxicity in patients receiving docetaxel chemotherapy

Kefeli U., Yumuk P. F., CEYHAN B., Dane F., Eroglu B., Cabuk D., et al.
45th Annual Meeting of the American-Society-of-Clinical-Oncology, Florida, Amerika Birleşik Devletleri, 29 Mayıs - 02 Haziran 2009, cilt.27, (Özet Bildiri) identifier

29. Results of randomized phase II trial combining Iressa (R) (gefitinib) and arimidex in women with advanced breast cancer (ABC). EORTC protocol 10021.

Mauriac L., Cameron D., Dirix L., Blot E., Piccart M., Marreaud S., et al.
31st Annual San Antonio Breast Cancer Symposium, San-Antonio, Kuzey Mariana Adaları, 10 - 14 Aralık 2008, cilt.69, (Özet Bildiri) Sürdürülebilir Kalkınma identifier

30. Memenin Apokrin Karsinomunda Hormon Reseptörleri ve Onkogenlerin Ekspresyonu

ERBARUT İ., KAYA H., BAŞARAN G., GÜLLÜOĞLU M. B.
17. Ulusal Patoloji Sempozyumu, Türkiye, 1 - 06 Ekim 2004

31. Outcome of adjuvant treatment in turkish breast cancer (BC) patients (PTS): Single institution experience

Cabuk D., BAŞARAN G., Iyikesici S., EKENEL M., Dane F., Teomete M., et al.
31st Congress of the European-Society-for-Medical-Oncology, İstanbul, Türkiye, 29 Eylül - 03 Ekim 2006, cilt.17, ss.109, (Özet Bildiri) identifier

32. Interstitial pneumonitis associated with docetaxel administration

Dane F., Topaloglu N., Abul Y., Yumuk P. F., Turhal N. S., Ceyhan B., et al.
31st Congress of the European-Society-for-Medical-Oncology, İstanbul, Türkiye, 29 Eylül - 03 Ekim 2006, cilt.17, ss.307, (Özet Bildiri) identifier

33. Trastuzumab beyond progression in metastatic breast cancer

Yanmaz M. T., Ozguroglu M., Ozturk B., Uygun K., BAŞARAN G., TURNA Z. H., et al.
31st Congress of the European-Society-for-Medical-Oncology, İstanbul, Türkiye, 29 Eylül - 03 Ekim 2006, cilt.17, ss.77, (Özet Bildiri) identifier

34. Stage I (T1N0M0) breast cancer (BC): Pathological characteristics and clinical outcome

BAŞARAN G., Cabuk D., Caglar H. B., Iyikesici S., Tebessum C., Gulluoglu B., et al.
31st Congress of the European-Society-for-Medical-Oncology, İstanbul, Türkiye, 29 Eylül - 03 Ekim 2006, cilt.17, ss.113, (Özet Bildiri) identifier

35. Serum Her2 extracellular domain (ECD) levels, pAkt and pMAPK expressions as potential markers for response to trastuzumab(T)-based therapy in metastatic breast cancer (MBC) patients (PTS). A Turkish oncology group study

BAŞARAN G., Guney N., SAİP P. M., Iyikesici S., Kaya H., YAZICI H., et al.
31st Congress of the European-Society-for-Medical-Oncology, İstanbul, Türkiye, 29 Eylül - 03 Ekim 2006, cilt.17, ss.90-91, (Özet Bildiri) identifier

36. Outcome of colon cancer patients receiving adjuvant chemotherapy in Marmara University Hospital

Dane F., Gumus M., Yumuk P. F., Iyikesici S., Ozturk A., BAŞARAN G., et al.
31st Congress of the European-Society-for-Medical-Oncology, İstanbul, Türkiye, 29 Eylül - 03 Ekim 2006, cilt.17, ss.130, (Özet Bildiri) identifier

37. Association between presence of HPV DNA and P53 in breast cancer patients

Yumuk P. F., Gumus M., Kaya H., Alam K., Dane F., Gulluoglu B., et al.
31st Congress of the European-Society-for-Medical-Oncology, İstanbul, Türkiye, 29 Eylül - 03 Ekim 2006, cilt.17, ss.110-111, (Özet Bildiri) identifier

38. Outcome of metastatic colorectal cancer patients receiving palliative chemotherapy in Marmara University Hospital

Dane F., Yumuk F., Gumus M., Iyikesici S., Tufan A., BAŞARAN G., et al.
31st Congress of the European-Society-for-Medical-Oncology, İstanbul, Türkiye, 29 Eylül - 03 Ekim 2006, cilt.17, ss.129, (Özet Bildiri) identifier

39. Outcome of patients with stage III and IV non-small cell lung cancer in Marmara University Hospital, Istanbul, Turkey

Teomete M., Yumuk P. F., Iyikesici M. S., Dane F., Basaran G., Cabuk D., et al.
31st Congress of the European-Society-for-Medical-Oncology, İstanbul, Türkiye, 29 Eylül - 03 Ekim 2006, cilt.17, ss.225-226, (Özet Bildiri) identifier

40. Outcome of adjuvant treatment in elderly Turkish breast cancer patients.

EKENEL M., BAŞARAN G., Dane F., Iyikesici S., Yumuk F., Turhal S.
41st Annual Meeting of the American-Society-of-Clinical-Oncology, Florida, Amerika Birleşik Devletleri, 13 - 17 Mayıs 2005, cilt.23, (Özet Bildiri) identifier

41. The prognostic impact of body mass index (BMI) in early breast cancer (BC) patients (pts).

Iyikesici M., KEFELİ U., BAŞARAN G., Dane F., EKENEL M., Yumuk P., et al.
41st Annual Meeting of the American-Society-of-Clinical-Oncology, Florida, Amerika Birleşik Devletleri, 13 - 17 Mayıs 2005, cilt.23, (Özet Bildiri) identifier

42. Clinical and pathological characteristics of early breast cancer (EBC) patients < 35 years old.

BAŞARAN G., Dane F., Iyikesici S., EKENEL M., Yumuk F., Turhal S.
41st Annual Meeting of the American-Society-of-Clinical-Oncology, Florida, Amerika Birleşik Devletleri, 13 - 17 Mayıs 2005, cilt.23, (Özet Bildiri) identifier

43. VEGF, HIF-1 alpha and CD34 expressions in gastric tumors (tms): Relationship with pathological factors and prognostic impact on survival.

Cabuk D., BAŞARAN G., Yumuk P., Celikel C., Dane F., Iyikesici M., et al.
41st Annual Meeting of the American-Society-of-Clinical-Oncology, Florida, Amerika Birleşik Devletleri, 13 - 17 Mayıs 2005, cilt.23, (Özet Bildiri) identifier

44. A quantitative study of tumor response and progression-free survival as surrogate endpoints for overall survival in first-line treatment of metastatic breast cancer

Burzykowski T., Piccart M., Sledge G., Carmichael J., Luck H., Mackey J., et al.
28th Annual San Antonio Breast Cancer Symposium, San-Antonio, Kuzey Mariana Adaları, 8 - 11 Aralık 2005, cilt.94, (Özet Bildiri) identifier

45. Effects of taxanes alone or in combination with anthracyclines on tumor response, progression-free survival and overall survival in first-line chemotherapy of patients with metastatic breast cancer: an analysis of 4,256 patients randomized in 12 trials

Piccart M., Burzykowski T., Sledge G., Carmichael J., Luck H., Mackey J., et al.
28th Annual San Antonio Breast Cancer Symposium, San-Antonio, Kuzey Mariana Adaları, 8 - 11 Aralık 2005, cilt.94, (Özet Bildiri) identifier

46. FOLFOX4 in metastatic colorectal cancer (MCRC) patients who progressed after infusional 5-FU/irinotecan based combination regimens.

Dane F., Yumuk P., Turhal N., Ekenel M., Basaran G., Iyikesici M., et al.
40th Annual Meeting of the American-Society-of-Clinical-Oncology, Louisiana, Amerika Birleşik Devletleri, 5 - 08 Haziran 2004, cilt.22, (Özet Bildiri) Sürdürülebilir Kalkınma identifier

47. Human papilloma virus: Is it a new etiological factor in breast cancer?

Gumus M., Yumuk F., Salepci T., Aliustacglu M., EKENEL M., BAŞARAN G., et al.
40th Annual Meeting of the American-Society-of-Clinical-Oncology, Louisiana, Amerika Birleşik Devletleri, 5 - 08 Haziran 2004, cilt.22, (Özet Bildiri) identifier

48. Is the incidence of anal canal cancers different in Moslem societies?

Cabuk D., Yumuk P., ABACIOGLU M. U., Demir G., Dane F., Gumus M., et al.
40th Annual Meeting of the American-Society-of-Clinical-Oncology, Louisiana, Amerika Birleşik Devletleri, 5 - 08 Haziran 2004, cilt.22, (Özet Bildiri) identifier

49. The expression pattern of members of the EGFR signaling pathway and its relation with the duration of response in metastatic breast cancer (BC) patients (pts) treated with endocrine therapy (ET)

Atalay G., Durbecq V., Larsimont D., Rouas G., Di Leo A., Leroy J., et al.
40th Annual Meeting of the American-Society-of-Clinical-Oncology, Louisiana, Amerika Birleşik Devletleri, 5 - 08 Haziran 2004, cilt.22, (Özet Bildiri) Sürdürülebilir Kalkınma identifier

50. Prognostic value of thymidylate synthase and cox-2 expression in colorectal cancer patients' tumors.

Aliustaoglu M., Gumus M., Midi A., Celikel C., EKENEL M., Yumuk F., et al.
40th Annual Meeting of the American-Society-of-Clinical-Oncology, Louisiana, Amerika Birleşik Devletleri, 5 - 08 Haziran 2004, cilt.22, (Özet Bildiri) identifier

51. Clinical outcome of breast cancer patients with liver metastases in the anthracycline-taxane era.

Atalay G., Biganzoli L., Renard F., Paridaens R., Batter V., Coleman R., et al.
25th San Antonio Breast Cancer Symposium, San-Antonio, Kuzey Mariana Adaları, 11 - 14 Aralık 2002, cilt.76, (Özet Bildiri) identifier

52. An EORTC IDBBC-ECSG randomized phase II trial of two different schedules of Caelyx (TM) in metastatic breast cancer patients.

Coleman R., Biganzoli L., Canney P., Mauriac L., Dirix L., Chollet P., et al.
25th San Antonio Breast Cancer Symposium, San-Antonio, Kuzey Mariana Adaları, 11 - 14 Aralık 2002, cilt.76, (Özet Bildiri) identifier
Kitaplar 7

1. Meme Kanserinde Sistemik Onkolojik Tedaviler

Başaran G. (E. Kurulu Üy.)
Meme Kanseri Cerrahisi ile Cerrahi Sonrası Tedavi Ve Onarımları - 2024 , Prof. Dr. Erol Benliler, E. Kurulu Üy., Türkiye Klinikleri Yayınevi, İstanbul, ss.37-43, 2024

2. Metastatik meme kanserinde endokrin tedavi: Yeni ajanların Klinik pratiğimize etkisi

Başaran G., Çabuk D.
HR+HER2- Meme Kanserinde Sistemik tedaviler ve güncel yaklaşımlar, Nil Molinas,Nilüfer Güler,FEyyaz Özdemir,İrfan Çiçin, Editör, Türkiye Klinikleri Yayınevi, Ankara, ss.7-360, 2022 Sürdürülebilir Kalkınma

3. Yaşlı hastalarda meme kanseri tedavisine yaklaşım

Çabuk D., Başaran G.
Geriatrik Onkoloji, KAraoglu A,Işık AT, Editör, Türkiye Klinikleri Yayınevi, Ankara, ss.1-134, 2020 Sürdürülebilir Kalkınma

4. Adjuvant Therapy for HER-2-Positive Early Breast Cancer

Başaran G., Çabuk D.
Breast Cancer, adnan aydıner,Abdullah İğici,Atilla Soran, Editör, Springer Nature, Basel, ss.1-824, 2019 Sürdürülebilir Kalkınma

5. Kanser Hastalarında Fizik Muayene

Başaran G., Çabuk D.
Kanser Hastasına YAklaşım, Nil Molinas,Haluk Onat, Editör, Nobel Tıp Kitapevi, İstanbul, ss.1-563, 2012 Sürdürülebilir Kalkınma

6. Hematolojik ve non-hematolojşk malinitelerde protokoller

Başaran G., Atasoy B. M., Atagündüz I., Abacıoglu M. U., Çetiner M., Kocakaya O.
Hematolojik ve non-hematolojşk malinitelerde protokoller, Mustafa Çetiner, Editör, Yelken Basım Yayım, İstanbul, ss.1-159, 2007

7. Node-positive breast cancer

Atalay G., Lohrisch C., Piccart M.
Breast cancer management, KAtia Tonkin,David M Reese,MAtti S Aapro,Aman A Buzdar, Editör, Lippincott Williams & Wilkins , Pennsylvania, ss.3-603, 2003 Sürdürülebilir Kalkınma
Metrikler

Yayın

174

Yayın (WoS)

130

Yayın (Scopus)

68

Atıf (WoS)

1869

H-İndeks (WoS)

18

Atıf (Scopus)

2515

H-İndeks (Scopus)

19

Atıf (Scholar)

14

H-İndeks (Scholar)

1

Proje

4

Açık Erişim

8
BM Sürdürülebilir Kalkınma Amaçları